WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H341486
CAS#: 669-50-1
Description: Xylocholine is a biochemical.
Hodoodo Cat#: H341486
Name: Xylocholine
CAS#: 669-50-1
Chemical Formula: C13H22NO+
Exact Mass: 208.17
Molecular Weight: 208.325
Elemental Analysis: C, 74.95; H, 10.64; N, 6.72; O, 7.68
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Xylocholine;
IUPAC/Chemical Name: Ethanaminium, 2-(2,6-dimethylphenoxy)-N,N,N-trimethyl-
InChi Key: RXYWAURTGUPANZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H22NO/c1-11-7-6-8-12(2)13(11)15-10-9-14(3,4)5/h6-8H,9-10H2,1-5H3/q+1
SMILES Code: Cc1cccc(c1OCC[N+](C)(C)C)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 208.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Orre M, Pennefather JN, Story ME, Haynes JM. The effects of P2 purinoceptor agonists on the isolated portal vein of the guinea pig. Eur J Pharmacol. 1996 Dec 5;316(2-3):229-36. PubMed PMID: 8982691.
2: Boura AL, Green AF. Noradrenergic neurone blocking agents. J Auton Pharmacol. 1981 Jun;1(3):255-67. PubMed PMID: 7040400.
3: Fielden R. The discovery of the noradrenergic neurone blocking action of TM10 (xylocholine). J Auton Pharmacol. 1981 Jun;1(3):251-4. PubMed PMID: 7040399.
4: Heitz DC, Brody MJ. Possible mechanism of histamine release during active vasodilatation. Am J Physiol. 1975 May;228(5):1351-7. PubMed PMID: 48345.
5: Prasad CM, Shah DS, Gulati OD. Some factors affecting the neuron blocking action of guanethidine, xylocholine, bretylium and debrisoquin. Jpn J Pharmacol. 1973 Dec;23(6):805-11. PubMed PMID: 4544694.
6: Hughes IE, Leak CM. Uptake of ( 14 C)xylocholine in mouse vas deferens after chemical sympathectomy. J Pharm Pharmacol. 1972 Sep;24(9):749-50. PubMed PMID: 4404086.
7: Dean HG, Hughes IE. Increased release of xylocholine (TM10) from guinea-pig vas deferens treated with amphetamine sulphate. J Pharm Pharmacol. 1972 Mar;24(3):183-8. PubMed PMID: 4402776.
8: Dean HG, Hughes IE. Effect of amphetamine on the uptake, release and effectiveness of xylocholine in the guinea-pig vas deferens. J Pharm Pharmacol. 1971 Aug;23(8):606-11. PubMed PMID: 4397745.
9: Coggon P, McPhail AT, Roe AM. Conformation of xylocholine. Nature. 1969 Dec 20;224(5225):1200-1. PubMed PMID: 5358339.
10: Schnizer W. [Effect of desipramine, cocaine and xylocholine on 5-hydroxytryptamine, adrenaline and vagus stimulation induced tonus decrease of smooth frog lung musculature]. Arzneimittelforschung. 1969 Apr;19(4):663-5. German. PubMed PMID: 5819171.
11: Clark ER, Jana M. The identification of the impurity responsible for the reported pressor activity of xylocholine. Br J Pharmacol Chemother. 1966 May;27(1):135-44. PubMed PMID: 5961461; PubMed Central PMCID: PMC1510797.
12: FIELDEN R, ROE AM, WILLEY GL. THE ADRENERGIC-NEURONE BLOCKING ACTION OF SOME COUMARAN COMPOUNDS. Br J Pharmacol Chemother. 1964 Dec;23:486-507. PubMed PMID: 14256809; PubMed Central PMCID: PMC1704011.
13: BHAGAT B. MODIFICATION OF THE EFFECTS OF GUANETHIDINE ON CARDIAC CATECHOL AMINES BY VARIOUS AGENTS. Br J Pharmacol Chemother. 1964 Apr;22:238-45. PubMed PMID: 14190459; PubMed Central PMCID: PMC1703988.
14: ROBERTS J, ITO R, REILLY J, CAIROLI VJ. INFLUENCE OF RESERPINE AND BETA TM 10 ON DIGITALIS-INDUCED VENTRICULAR ARRHYTHMIA. Circ Res. 1963 Aug;13:149-58. PubMed PMID: 14047640.
15: BURN JH, FROEDE H. The action of substances which block sympathetic postganglionic nervous transmission. Br J Pharmacol Chemother. 1963 Apr;20:378-87. PubMed PMID: 14017105; PubMed Central PMCID: PMC1703641.
16: WILLEY GL. Effect of antisympathomimetic drugs on the plasma concentrations of catechol amines. Br J Pharmacol Chemother. 1962 Dec;19:365-74. PubMed PMID: 14000807; PubMed Central PMCID: PMC1482210.
17: DAY MD. Effect of sympathomimetic amines on the blocking action of guanethidine, bretylium and xylocholine. Br J Pharmacol Chemother. 1962 Apr;18:421-39. PubMed PMID: 13884064; PubMed Central PMCID: PMC1482112.
18: AVIADO DM. Sympathetic nerve blocking drugs for the treatment of hypertension. TM-10, beta TM-10, bretylium and guanethidine. Am J Med Sci. 1961 May;241:650-61. PubMed PMID: 13685282.
